Vytorin Outcomes Comparison To Zocor Anticipated In 2008, Merck/Schering-Plough Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Following delays in reporting data from ENHANCE, companies narrowed the study’s primary endpoint on the advice of an independent panel.
You may also be interested in...
Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction
Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.
Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction
Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.
Lack Of Data Released From Merck/Schering-Plough Vytorin Trial Spurs House Inquiry
Companies also reject expert panel recommendation to change the primary endpoint for the ENHANCE trial.